创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

李臣诚, 徐寒梅, 胡加亮. 针对IL-4/IL-4R信号通路的肿瘤治疗策略研究进展[J]. 药学进展, 2019, 43(5): 371-378.
引用本文: 李臣诚, 徐寒梅, 胡加亮. 针对IL-4/IL-4R信号通路的肿瘤治疗策略研究进展[J]. 药学进展, 2019, 43(5): 371-378.
LI Chencheng, XU Hanmei, HU Jialiang. Researches Advances in Tumor Therapy Targeting IL-4/IL-4R Signaling Pathway[J]. Progress in Pharmaceutical Sciences, 2019, 43(5): 371-378.
Citation: LI Chencheng, XU Hanmei, HU Jialiang. Researches Advances in Tumor Therapy Targeting IL-4/IL-4R Signaling Pathway[J]. Progress in Pharmaceutical Sciences, 2019, 43(5): 371-378.

针对IL-4/IL-4R信号通路的肿瘤治疗策略研究进展

Researches Advances in Tumor Therapy Targeting IL-4/IL-4R Signaling Pathway

  • 摘要: 目前对于原发性上皮肿瘤的治疗已取得较多进展,但转移性肿瘤死亡率仍很高,且针对转移性肿瘤治疗的进展有限。研究表明,IL-4/IL-4R信号通路不仅在免疫系统中具有很重要的作用,且IL-4R在很多上皮肿瘤细胞中有过表达的现象,IL-4/IL-4R信号通路在上皮肿瘤的存活、增殖、迁移和侵袭中具有很强的促进作用。美国FDA已批准了几种靶向IL-4/IL-4R信号通路的药物用于哮喘的治疗,目前这些药物均又被用于肿瘤治疗的开发。综述针对IL-4/IL-4R信号通路的肿瘤治疗策略研究进展,分析近年来一些新的靶向IL-4/IL-4R的肿瘤治疗方法,旨在为相关药物的研发提供参考。

     

    Abstract: Currently, significant progress has been made in the treatment of primary epithelial tumors. However, the mortality rate of metastatic tumor remains very high and limited progress has been made in its treatment. Studies have shown that IL-4/IL-4R signaling pathway not only plays an essential role in the immune system but also has a strong promoting effect on the survival, proliferation, migration, and invasion of epithelial tumor cells due to its overexpression in several types of epithelial tumor cells. FDA has approved several drugs targeting IL-4/IL-4R signaling pathway for the treatment of asthma. These drugs are currently under the development for cancer treatment. This article reviewed research advances in tumor therapeutic strategies that target IL-4/IL-4R signaling pathway and analyzed some recently developed new therapeutic strategies targeting IL-4/IL-4R pathway, so as to provide reference for the research and development of new drugs.

     

/

返回文章
返回